TrialCancer2025

Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study.

Carolina Schinke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.